Issued 2026-08-13 at $10.44 · now $10.51 (2026-08-13, +0.7% since)
Based on its own history, a month from the 2026-08-13 close, OLMA has typically landed between $6.93 and $16.12 — a range of −33.6% to +54.4% from the issuance price $10.44.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
1,415 overlapping 1 month windows · 2020-11-19 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($10.44) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where OLMA has typically landed a month from the 2026-08-13 close of $10.44 — the range is history, not a prediction.
- now $10.51 (+0.7%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $9.94 (-4.8%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $8.2–$11.69
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $6.93–$16.12
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2021-11-11 | −66.6% | −66.6% | +0.0% |
| 2021-11-12 | −66.0% | −66.5% | +0.0% |
| 2021-11-15 | −65.2% | −65.6% | +0.6% |
| 3 best | |||
| 2025-11-12 | +344.5% | −1.5% | +344.5% |
| 2025-11-13 | +331.7% | +0.0% | +351.3% |
| 2025-11-11 | +303.5% | −3.1% | +303.5% |
1,415 overlapping windows · 2020-11-19 – 2026-08-13 · not cherry-picked
Pending catalysts
- 2026-10-31 — Trial primary completion: Phase 3 primary completion: OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer (source, as of 2026-08-14)
- December 2028 — Trial primary completion: Phase 3 primary completion: Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~6 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.